---
document_datetime: 2024-07-17 14:24:05
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lenalidomide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.1196055
conversion_datetime: 2025-12-25 07:34:30.061312
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lenalidomide Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0016/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 12/07/2024                          |                                             | SmPC, Annex II and PL            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                              |            |            |             |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IA/0015            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/02/2024 | n/a        |             |                                   |
| II/0014            | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 31/08/2023 | n/a        |             |                                   |
| PSUSA/1838/ 202212 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/08/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0013/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 12/06/2023 | 29/06/2023 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                    | the MAH                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                  |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                          | 04/10/2022 | 29/06/2023 | SmPC and PL      |                                                                                                                                           |
| IAIN/0010/G        | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 15/08/2022 | n/a        |                  |                                                                                                                                           |
| N/0009             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                   | 15/07/2022 | 29/06/2023 | Labelling and PL |                                                                                                                                           |
| N/0008             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                   | 28/02/2022 | 08/07/2022 | PL               |                                                                                                                                           |
| IA/0007            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                       | 06/10/2021 | n/a        |                  |                                                                                                                                           |
| PSUSA/1838/ 202012 | Periodic Safety Update EU Single assessment - lenalidomide                                                                                                                                                                                                                                                                                                                                         | 22/07/2021 | 16/09/2021 |                  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1838/202012. |
| IB/0006            | B.II.f.1.b.1 - Stability of FP - Extension of the shelf                                                                                                                                                                                                                                                                                                                                            | 13/09/2021 | 08/07/2022 | SmPC             | To update section 6.3 of the Summary of Product                                                                                           |

<div style=\"page-break-after: always\"></div>

|             | life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       | Characteristics.                                                                                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------|
| IAIN/0005/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                         | 13/08/2021 | 08/07/2022 | Annex II and PL       |                                                                                                                    |
| IB/0004/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 19/07/2021 | 12/08/2021 | SmPC, Annex II and PL |                                                                                                                    |
| IB/0003/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/05/2021 | 12/08/2021 | SmPC, Labelling and   | Change in the pack size of the finished product outside the range of the currently approved pack size to add 7 x 1 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   | PL   | capsules in (PVC/Aclar/alu) unit dose blister for the 5 mg, 10 mg & 15 mg strengths, new pack sizes of 7 x 1 capsules (unit dose) for the 2.5 mg, 7.5 mg, 20 mg & 25 mg strengths (EU/1/20/1490/019, EU/1/20/1490/021, EU/1/20/1490/025 and EU/1/20/1490/026) and new pack size of 7 capsules in blister (PVC/Aclar/alu) for the 10 mg strength (EU/1/20/1490/022). The marketing authorisation holder took the opportunity to align the PI to the latest QRD template (version 10.2) and to include editorial changes are in the linguistic versions of the Annexes for ES, HR and SK.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IA/0001   | A.7 - Administrative change - Deletion of manufacturing sites   | 05/03/2021   | 12/08/2021   | SmPC, Annex II and PL   |
|-----------|-----------------------------------------------------------------|--------------|--------------|-------------------------|